Dipivefrine was first described by 1975.[9] It is widely marketed throughout the world.[10] However, it is no longer available in the United States.[11]
Use in narrow-angle glaucoma may be dangerous because it could make the eye susceptible to an attack of angle closure,[3] causing an increase in pressure and pain and possibly loss of vision.
Side effects
The most common side effects of dipivefrine are burning, stinging, and other irritations of the eye. Possible but uncommon side effects are the same as those of epinephrine and include tachycardia (fast heartbeat), hypertension (high blood pressure) and arrhythmias (irregular heartbeat).[3]
The experimental log P of dipivefrine is 1.7 and its predicted log P ranges from 1.49 to 3.71.[6][1][12] It is dramatically more lipophilic (600-fold) than epinephrine,[7][8][4] which is highly hydrophilic and has a log P of -1.37.[13] The lipophilicity of dipivefrine allows it to penetrate the cornea much more readily (17-fold) than epinephrine.[7][8][4] Eye drops containing 0.1% dipivefrine have similar effectiveness to conventional eye drops containing 2% epinephrine in lowering intraocular pressure.[4]
Dipivefrine is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while dipivefrin is its USANTooltip United States Adopted Name and dipivefrina is its DCITTooltip Denominazione Comune Italiana.[14][10][15] In the case of the hydrochloridesalt, dipivefrine hydrochloride is its BANMTooltip British Approved Name while dipivefrin hydrochloride is its USANTooltip United States Adopted Name and JANTooltip Japanese Accepted Name.[14][10][15]
Synonyms of dipivefrine include epinephrine pivalate, adrenaline pivalate, and dipivalyl epinephrine, among others.[14][10]
Dipivefrine has been sold under brand names including Diopine, Glaucothil, Pro-Epinephrine, Propine, Thilodrin, and Vistapine, among many others.[14][10]
^Arthur S, Cantor LB (September 2011). "Update on the role of alpha-agonists in glaucoma management". Exp Eye Res. 93 (3): 271–283. doi:10.1016/j.exer.2011.04.002. PMID21524649.
^ abMcClure DA (1 June 1975). "The Effect of a Pro-drug of Epinephrine (Dipivalyl Epinephrine) in Glaucoma—General Pharmacology, Toxicology, and Clinical Experience". Pro-drugs as Novel Drug Delivery Systems. ACS Symposium Series. Vol. 14. Washington, D. C.: American Chemical Society. pp. 225–235. doi:10.1021/bk-1975-0014.ch006. ISBN978-0-8412-0291-7.